Novo Nordisk Applies for Approval of Game-changing Weight-lo…

图片地址：https://images.tmtpost.com/uploads/images/2023/06/cf562aad545948242e37834de4190203_1686064987.jpeg

BEIJING, June 6 (TiPost) -- Novo Nordisk has submitted application for the approval of semaglutide injection for weight loss to China's regulator, according to the website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration.Semaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. It is a hypoglycemic drug with weight loss effectsThe exploration of GLP-1 drugs in the